KTOV News and Press, Kitov Pharma Ltd. From 02/11/20

TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today provided a corporate update and announced financial...

Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune ...

TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt from the European Patent Office (...

Kitov Pharma (NASDAQ: KTOV ) closes its acquisition of privately-held, FameWave Ltd. The acquisition adds CM-24 inhibitor to the company's oncology pipeline. More news on: Kitov Pharma Ltd, Healthcare stocks news, Read more ...

Concurrent with the close of the transaction, OrbiMed, Pontifax and Arkin are investing $3.5 million in Kitov and will each hold approximately 11% of the company’s shares on a non-diluted basis Acquisition strengthens Kitov’s oncology pipeline with the addition of novel...

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that, after its delivery of written notic...

Kitov Pharma ( KTOV ) recently announced that they amended their Consensi marketing and distribution agreement with Coeptis Pharmaceuticals in the United States. As a result, Kitov will receive up to $99.5M in milestone and reimbursement payments. In addition, Kitov will get double-digit r...

Kitov Pharma (NASDAQ: KTOV ) has  amended  the marketing and distribution agreement with Coeptis Pharmaceuticals and provided an update on the upcoming launch of Consensi in the U.S. More news on: Kitov Pharma Ltd, Healthcare stocks news, Stocks on the move, Read more ...

In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royalties Coeptis Pharmaceuticals has engaged a distribution partner with an established sales network and access to thousands of pharmacies nationwide TEL AVI...

Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) --   Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor i...